Titre
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Peters, S.
Auteure/Auteur
Weder, W.
Auteure/Auteur
Dafni, U.
Auteure/Auteur
Kerr, K.M.
Auteure/Auteur
Bubendorf, L.
Auteure/Auteur
Meldgaard, P.
Auteure/Auteur
O'Byrne, K.J.
Auteure/Auteur
Wrona, A.
Auteure/Auteur
Vansteenkiste, J.
Auteure/Auteur
Felip, E.
Auteure/Auteur
Marchetti, A.
Auteure/Auteur
Savic, S.
Auteure/Auteur
Lu, S.
Auteure/Auteur
Smit, E.
Auteure/Auteur
Dingemans, A.M.
Auteure/Auteur
Blackhall, F.H.
Auteure/Auteur
Baas, P.
Auteure/Auteur
Camps, C.
Auteure/Auteur
Rosell, R.
Auteure/Auteur
Stahel, R.A.
Auteure/Auteur
Contributrices/contributeurs
Stahel, R.A.
Rosell, R.
Blackhall, F.
Dafni, U.
Kerr, K.M.
Taron, M.
Molina, M.Á.
Bubendorf, L.
Weder, W.
Thunnissen, E.
Peters, S.
Hiltbrunner, A.
Kammler, R.
Marbot, M.
Maibach, R.
Ruepp, B.
Dafni, U.
Kassapian, M.
Polydoropoulou, V.
Poulopoulou, S.
Meldgaard, P.
Hager, H.
Højsgaard, A.
Weder, W.
Soltermann, A.
Tischler, V.
Storz, M.
Vrugt, B.
Friess, M.
Curioni, A.
O'Byrne, K.
Finn, S.
McGovern, E.
Young, V.
Gray, S.
Enright, C.
Gately, K.
Walker, J.
Barr, M.
Vansteenkiste, J.
Verbeken, E.
Nackaerts, K.
Dooms, C.
Oyen, C.
Peeters, L.
Lepers, S.
Vliegen, L.
Roskams, T.
Van Der Borght, S.
Vandenberghe, P.
Dziadziuszko, R.
Biernat, W.
Sejda, A.
Rzyman, W.
Jassem, J.
Maciejewska-Izdebska, A.
Felip, E.
Hernandez-Losa, J.
Sansano, I.
Canela, M.
Garrell, N.M.
Marchetti, A.
Malatesta, S.
Mucilli, F.
Irtelli, L.
Buttitta, F.
Bubendorf, L.
Savic, S.
Lardinois, D.
Zippelius, A.
Kerr, K.M.
Nicolson, M.
Remmen, H.
Stevenson, D.A.
Price, N.
Lu, S.
Jie, Z.
Tan, Q.
Cheng, Z.
Thunnissen, E.
Smit, E.
van Setten, C.
Dingemans, A.M.
Speel, E.J.
Maessen, J.
Bendek, M.
Adjei, A.A.
Cheney, R.
Pine, M.B.
Reid, M.
Morrison, C.
Taylor, E.
Blackhall, F.
Nonaka, D.
Harris, J.
Wallace, A.
Shah, R.
Summers, Y.
Quinn, A.M.
Booton, R.
Baas, P.
de Jong, J.
Klomp, H.
Mahn, M.
Obbink, M.G.
Rosenberg, E.H.
Nederlof, P.
Camps, C.
Jantus-Lewintre, E.
Groupes de travail
ETOP Lungscape Investigators
Liens vers les personnes
Liens vers les unités
ISSN
1556-1380
Statut éditorial
Publié
Date de publication
2014-11
Volume
9
Numéro
11
Première page
1675
Dernière page/numéro d’article
1684
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
The Lungscape project was designed to address the impact of clinical, pathological, and molecular characteristics on outcome in resected non-small- cell lung cancer (NSCLC).
A decentralized biobank with fully annotated tissue samples was established. Selection criteria for participating centers included sufficient number of cases, tissue microarray building capability, and documented ethical approval. Patient selection was based on availability of comprehensive clinical data, radical resection between 2003 and 2009 with adequate follow-up, and adequate quantity and quality of formalin-fixed tissue.
Fifteen centers contributed 2449 cases. The 5-year overall survival (OS) was 69.6% and 63.6% for stages IA and IB, 51.6% and 47.7% for stages IIA and IIB, and 29.0% and 13.0% for stages IIIA and IIIB, respectively (p < 0.001). Median and 5-year relapse-free survival (RFS) were 52.8 months and 47.3%, respectively. Distant relapse was recorded for 44.4%, local for 26.0%, and both for 16.9% of patients. Based on multivariate analysis for the OS, RFS, and time to relapse, the factors significantly associated with all of them are performance status and pathological stage.
The aim of this report is to present the results from Lungscape, the first large series reporting on NSCLC surgical outcome measured not only by OS but also by RFS and time to relapse and including multivariate analysis by significant clinical and pathological prognostic parameters. As tissue from all patients is preserved locally and is available for detailed molecular investigations, Lungscape provides an excellent basis to evaluate the influence of molecular parameters on the disease outcome after radical resection, besides providing an overview of the molecular landscape of stage I to III NSCLC.
A decentralized biobank with fully annotated tissue samples was established. Selection criteria for participating centers included sufficient number of cases, tissue microarray building capability, and documented ethical approval. Patient selection was based on availability of comprehensive clinical data, radical resection between 2003 and 2009 with adequate follow-up, and adequate quantity and quality of formalin-fixed tissue.
Fifteen centers contributed 2449 cases. The 5-year overall survival (OS) was 69.6% and 63.6% for stages IA and IB, 51.6% and 47.7% for stages IIA and IIB, and 29.0% and 13.0% for stages IIIA and IIIB, respectively (p < 0.001). Median and 5-year relapse-free survival (RFS) were 52.8 months and 47.3%, respectively. Distant relapse was recorded for 44.4%, local for 26.0%, and both for 16.9% of patients. Based on multivariate analysis for the OS, RFS, and time to relapse, the factors significantly associated with all of them are performance status and pathological stage.
The aim of this report is to present the results from Lungscape, the first large series reporting on NSCLC surgical outcome measured not only by OS but also by RFS and time to relapse and including multivariate analysis by significant clinical and pathological prognostic parameters. As tissue from all patients is preserved locally and is available for detailed molecular investigations, Lungscape provides an excellent basis to evaluate the influence of molecular parameters on the disease outcome after radical resection, besides providing an overview of the molecular landscape of stage I to III NSCLC.
PID Serval
serval:BIB_C367F4947944
PMID
Open Access
Oui
Date de création
2018-01-16T12:41:24.776Z
Date de création dans IRIS
2025-05-21T03:30:33Z